April 2011
Volume 52, Issue 14
ARVO Annual Meeting Abstract  |   April 2011
Visual Impairment, Visual Function And Quality Of Life Among Uveitis Patients In A North American Population
Author Affiliations & Notes
  • Karin M. Oliver
    Ophthalmology, McGill University, Montreal, Quebec, Canada
  • Laurence Jaworski
    Ophthalmology, Université de Montreal, Montreal, Quebec, Canada
  • Elodie Samson
    Ophthalmology, Hôpital Maisonneuve Rosemont, Montreal, Quebec, Canada
  • Ellen Freeman
    Ophthalmology, Université de Montreal, Montreal, Quebec, Canada
  • Marie-Lyne Bélair
    Ophthalmology, Montreal, Montreal, Quebec, Canada
  • Marie-Josée Aubin
    Ophthalmology, Université de Montreal, Montreal, Quebec, Canada
  • Éric Fortin
    Ophthalmology, Université de Montreal, Montreal, Quebec, Canada
  • Footnotes
    Commercial Relationships  Karin M. Oliver, None; Laurence Jaworski, None; Elodie Samson, None; Ellen Freeman, None; Marie-Lyne Bélair, None; Marie-Josée Aubin, None; Éric Fortin, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 4280. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Karin M. Oliver, Laurence Jaworski, Elodie Samson, Ellen Freeman, Marie-Lyne Bélair, Marie-Josée Aubin, Éric Fortin; Visual Impairment, Visual Function And Quality Of Life Among Uveitis Patients In A North American Population. Invest. Ophthalmol. Vis. Sci. 2011;52(14):4280.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

To evaluate the epidemiology and course of uveitis in a North American tertiary care center and to determine the relationship between visual impairment, visual functioning and the global quality of life in patients with uveitis.


A detailed chart review, best corrected Snellen acuity and 2 validated questionnaires were performed on 194 randomly selected consenting patients with a clinical diagnosis of uveitis at a Montreal-based tertiary care uveitis clinic between February and May 2010. All subjects were administered the Visual Function 14 (VF-14) and the Medical Outcomes Study 36-item short-form (SF-36) surveys validated for the French language. Kruskal-Wallis tests, Wilcoxon rank-sum tests, and Spearman correlation analysis were used to test for statistical significance.


The uveitis was classified as anterior(37%), anterior/intermediate(19%), intermediate(9%), posterior(11%) and panuveitis(19%). The course of disease was chronic in 79% of patients and the mean duration of follow-up was 54.8 months. Significant ocular complications associated with uveitis were cataract(68%), cystoid macular edema(37%) and glaucoma(22%). Patients who had a persistent duration of disease scored significantly lower (p<0.05) than those with limited disease duration on the VF-14 and social functioning domain of the SF-36 questionnaire. Of particular importance, patients who were taking 1 or more systemic immunosuppressants scored significantly lower (p<0.05) on several SF-36 subscales than non-immunosuppressed patients. Those with a history of intravitreal triamcinolone or bevacizumab injections had lower VF-14 and certain SF-36 subscale scores. Logmar visual acuity in the better eye correlated with VF-14, SF-36 role physical, vitality, and social functioning subscales (P<0.05).


Patients with uveitis who have a persistent duration of disease, who require systemic immunosuppression and/or intravitreal injections report more functional impairment than other uveitis patients. As uveitis often affects individuals during the most productive years of their adult lives, the use of these questionnaires along with demographic and disease-specific data may help clinicians to better establish the impact of disease severity on uveitis patients’ quality of life.

Keywords: uveitis-clinical/animal model • quality of life • visual acuity 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.